DMRA
The table below shows Damora Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $23.78M | $1.42M | $1.47M | $678.00K | $1.09M | $1.83M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.03M |
| $1.74M |
| $1.96M |
| $1.92M |
| $2.75M |
| $2.77M |
| Operating income | -$30.81M | -$3.16M | -$3.42M | -$2.60M | -$3.84M | -$5.58M |
| Income tax | $42.00K | $0.00 | $4.00K | $2.00K | $7.00K | $42.00K |
| Net income | -$27.78M | -$3.13M | -$3.44M | -$2.53M | -$3.88M | -$5.34M |
| EPS (diluted) | -$0.62 | -$2.36 | -$2.60 | -$1.92 | -$3.39 | -$4.92 |